We are live on ! Find out more
ABBV icon

AbbVie

4,231 hedge funds and large institutions have $335B invested in AbbVie in 2026 Q2 according to their latest regulatory filings, with 285 funds opening new positions, 1,929 increasing their positions, 1,545 reducing their positions, and 112 closing their positions.

New
Increased
Maintained
Reduced
Closed

154% more first-time investments, than exits

New positions opened: 285 | Existing positions closed: 112

25% more repeat investments, than reductions

Existing positions increased: 1,929 | Existing positions reduced: 1,545

19% more capital invested

Capital invested by funds: $282B → $335B (+$53.4B)

17% more call options, than puts

Call options by funds: $3.71B | Put options by funds: $3.17B

14% more funds holding in top 10

Funds holding in top 10: 175199 (+24)

3% more funds holding

Funds holding: 4,1144,231 (+117)

2.11% more ownership

Funds ownership: 73.41%75.52% (+2.1%)

Holders
4,231
Holders Change
+117
Holders Change %
+2.84%
% of All Funds
50.71%
Holding in Top 10
199
Holding in Top 10 Change
+24
Holding in Top 10 Change %
+13.71%
% of All Funds
2.39%
New
285
Increased
1,929
Reduced
1,545
Closed
112
Calls
$3.71B
Puts
$3.17B
Net Calls
+$539M
Net Calls Change
+$825M

ABBV Hedge Fund Activity: Q2 2026 in Review

4,231 of the 8,343 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q2 2026, worth a combined $335B — up 19% from $282B a quarter earlier.

Buyers outnumbered sellers: 285 funds opened new ABBV positions and 112 closed out — a net gain of 173 holders — while 1,929 added to existing stakes and 1,545 trimmed.

The largest buyer was Franklin Resources, adding an estimated $1.16B. The largest seller was JP Morgan Chase, cutting an estimated $1.91B.

  • 4,231 institutional investors held AbbVie (ABBV) as of Q2 2026, up from 4,114 in Q1 2026.
  • Funds reported $335B of AbbVie stock for Q2 2026, up 19% quarter-over-quarter.
  • 285 funds opened new AbbVie positions in Q2 2026 and 112 closed out, a net change of +173 holders.
  • The largest AbbVie buyer in Q2 2026 was Franklin Resources, an estimated $1.16B added.
  • The largest AbbVie seller in Q2 2026 was JP Morgan Chase, an estimated $1.91B sold.

Based on aggregated 13F filings for Q2 2026.